Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, surgical products specialist NuVasive
With that in mind, let's take a closer look at NuVasive's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||San Diego, Calif. (1997)|
|Market Cap||$660.3 million|
|Trailing-12-Month Revenue||$589.2 million|
|Management||Chairman/CEO Alexis Lukianov
President/COO Keith Valentine
|Return on Equity (average, past 3 years)||2.7%|
|Cash/Debt||$241.8 million / $400.3 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 90% of the 187 members who have rated NuVasive believe the stock will outperform the S&P 500 going forward.
This is a technological medical device company innovating at the forefront of minimally disruptive surgical products and procedures for the spine. With their surgical techniques and products, spine surgery patients have less blood loss, less time in hospital, and significantly quicker recovery time both initially after surgery and longer-term -- with patients typically going back to work within 4-6 weeks versus the more usual 6 months.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, NuVasive may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.